United States (US) Generics Market Summary, Competitive Analysis and Forecast to 2027
Summary
Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2017-22, and forecast to 2027). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
- The US generics market had total revenues of $69.9 billion in 2022, representing a compound annual growth rate (CAGR) of 2.2% between 2017 and 2022.
- Market consumption volume increased with a CAGR of 0.3% between 2017 and 2022, to reach a total of 91.4 % in 2022.
- 9 out of 10 prescriptions written in the United States, according to the FDA, are for generic drugs. Increased access to generic drugs encourages market competition, which lowers the cost of treatment and broadens access to healthcare for more patients.
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the United States
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts
- What was the size of the United States generics market by value in 2022?
- What will be the size of the United States generics market in 2027?
- What factors are affecting the strength of competition in the United States generics market?
- How has the market performed over the last five years?
- Who are the top competitors in the United States's generics market?
- 1 Executive Summary
- 1.1. Market value
- 1.2. Market value forecast
- 1.3. Market volume
- 1.4. Market volume forecast
- 1.5. Geography segmentation
- 1.6. Market rivalry
- 1.7. Competitive landscape
- 2 Market Overview
- 2.1. Market definition
- 2.2. Market analysis
- 3 Market Data
- 3.1. Market value
- 3.2. Market volume
- 4 Market Segmentation
- 4.1. Geography segmentation
- 5 Market Outlook
- 5.1. Market value forecast
- 5.2. Market volume forecast
- 6 Five Forces Analysis
- 6.1. Summary
- 6.2. Buyer power
- 6.3. Supplier power
- 6.4. New entrants
- 6.5. Threat of substitutes
- 6.6. Degree of rivalry
- 7 Competitive Landscape
- 7.1. Who are the leading players?
- 7.2. What are the strengths of the leading player?
- 7.3. Have there been any recent developments in the market?
- 8 Company Profiles
- 8.1. Teva Pharmaceutical Industries Limited
- 8.2. Viatris Inc.
- 8.3. Pfizer Inc.
- 8.4. Novartis AG
- 9 Macroeconomic Indicators
- 9.1. Country data
- 10 Appendix
- 10.1. Methodology
- 10.2. Industry associations
- 10.3. Related MarketLine research
- 10.4. About MarketLine
- List of Tables
- Table 1: United States generics market value: $ million, 2017-22
- Table 2: United States generics market volume: %, 2017-22
- Table 3: United States generics market geography segmentation: $ million, 2022
- Table 4: United States generics market value forecast: $ million, 2022-27
- Table 5: United States generics market volume forecast: %, 2022-27
- Table 6: Teva Pharmaceutical Industries Limited: key facts
- Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
- Table 8: Teva Pharmaceutical Industries Limited: Key Employees
- Table 9: Viatris Inc.: key facts
- Table 10: Viatris Inc.: Annual Financial Ratios
- Table 11: Viatris Inc.: Key Employees
- Table 12: Viatris Inc.: Key Employees Continued
- Table 13: Pfizer Inc.: key facts
- Table 14: Pfizer Inc.: Annual Financial Ratios
- Table 15: Pfizer Inc.: Key Employees
- Table 16: Pfizer Inc.: Key Employees Continued
- Table 17: Novartis AG: key facts
- Table 18: Novartis AG: Annual Financial Ratios
- Table 19: Novartis AG: Key Employees
- Table 20: Novartis AG: Key Employees Continued
- Table 21: United States size of population (million), 2018-22
- Table 22: United States gdp (constant 2005 prices, $ billion), 2018-22
- Table 23: United States gdp (current prices, $ billion), 2018-22
- Table 24: United States inflation, 2018-22
- Table 25: United States consumer price index (absolute), 2018-22
- Table 26: United States exchange rate, 2018-22
- List of Figures
- Figure 1: United States generics market value: $ million, 2017-22
- Figure 2: United States generics market volume: %, 2017-22
- Figure 3: United States generics market geography segmentation: % share, by value, 2022
- Figure 4: United States generics market value forecast: $ million, 2022-27
- Figure 5: United States generics market volume forecast: %, 2022-27
- Figure 6: Forces driving competition in the generics market in the United States, 2022
- Figure 7: Drivers of buyer power in the generics market in the United States, 2022
- Figure 8: Drivers of supplier power in the generics market in the United States, 2022
- Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United States, 2022
- Figure 10: Factors influencing the threat of substitutes in the generics market in the United States, 2022
- Figure 11: Drivers of degree of rivalry in the generics market in the United States, 2022
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook